Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZE77-0273
- Development stage
- Preclinical
- Lead developer
- Eilean Therapeutics
- Modality
- Small Molecules
- Administration
- Not Specified
01
Overview
ZE77-0273 is a reversible small-molecule drug candidate developed by Eilean Therapeutics. It acts as a pan-EGFR inhibitor, demonstrating broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer (NSCLC) and has a high selectivity index versus wild-type EGFR. It is designed to be brain- and lung-permeable, offering an excellent safety and tolerability profile[1][8].
- Brand names
- ZE77-0273ZE-77-0273ZE 77-0273
- Other names
- ZE77-0273ZE-77-0273ZE 77-0273
02
Targets
Beyond the preview
Go deeper on ZE77-0273.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZE77-0273.